Literature DB >> 12562232

Clinical-histopathologic concordance of tumors of the nervous system at the Manuel Velasco Suárez National Institute of Neurology and Neurosurgery in Mexico City.

Leora Velásquez-Pérez1, María Esther Jiménez-Marcial.   

Abstract

CONTEXT: When making a diagnosis, the main purpose of clinicians should not be to achieve certainty, but to decrease diagnostic uncertainty in order to make optimal therapeutic decisions. Diagnostic concordance is an essential characteristic if a measurement is to be considered scientific. In the case of tumors of the nervous system (TNS), one of the most accurate diagnostic tests is magnetic resonance imaging. However, histopathologic analyses are essential, because they refine the diagnosis, benefit the patient, and improve our understanding of the disease. By determining the clinical-histopathologic correlation of TNS in one of the main neurologic centers in Mexico, we sought to project reliable morbidity and/or mortality statistics.
OBJECTIVE: To assess clinical and histopathologic diagnostic agreement in cases involving TNS admitted to the Manuel Velasco Suárez National Institute of Neurology and Neurosurgery between 1990 and 1999.
DESIGN: Cross-sectional diagnostic concordance study, including all clinical hospital records of patients with histopathologically diagnosed TNS, classified according to World Health Organization criteria.
RESULTS: Among 2041 TNS cases, the 3 most frequent types were those affecting the neuroepithelial tissue (32.9%), tumors of the sellar region (29.2%), and tumors of the meninges (25.6%). We found that, overall, clinical-histopathologic concordance for these 3 categories was substantial and statistically significant.
CONCLUSIONS: Tumors of the nervous system constitute a heterogeneous group of neoplasms. In the present study, clinical diagnoses substantially agreed with pathologic diagnoses. The a priori clinical diagnosis allowed prompt treatment even before diagnostic confirmation by histopathologic analysis, which is the best way to confirm, clarify, and correct a diagnosis.

Entities:  

Mesh:

Year:  2003        PMID: 12562232     DOI: 10.5858/2003-127-187-CHCOTO

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  4 in total

1.  Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin.

Authors:  Mario Orozco-Morales; Francisco-Javier Sánchez-García; Patricia Guevara-Salazar; Oscar Arrieta; Norma Y Hernández-Pedro; Aurora Sánchez-García; Rodolfo Perez-Madrigal; Edgar Rangel-López; Benjamín Pineda; Julio Sotelo
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-27       Impact factor: 4.553

2.  Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.

Authors:  Roxana Magaña-Maldonado; Karen Manoutcharian; Norma Y Hernández-Pedro; Edgar Rangel-López; Verónica Pérez-De la Cruz; César Rodríguez-Balderas; Julio Sotelo; Benjamín Pineda
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-14       Impact factor: 4.553

Review 3.  Temozolomide for high grade glioma.

Authors:  Michael G Hart; Ruth Garside; Gabriel Rogers; Ken Stein; Robin Grant
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

Review 4.  Immunological Evasion in Glioblastoma.

Authors:  Roxana Magaña-Maldonado; Elda Georgina Chávez-Cortez; Nora Karen Olascoaga-Arellano; Mariana López-Mejía; Fernando Manuel Maldonado-Leal; Julio Sotelo; Benjamín Pineda
Journal:  Biomed Res Int       Date:  2016-05-15       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.